1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

3/29/2009 “Adoptive T cell therapy of B cell malignancies: Of mice and men”, ATTACK,2nd Cellular Therapy of Cancer Symposium, Milan, Italy5/28/2009 “Treatment of B cell malignancies with CD19-targeted T cells”, AmericanSociety of Gene Therapy Annual Meeting, Outstanding New InvestigatorSymposium, San Diego CA10/28/2009 “Adoptive cell therapy of cancer utilizing genetically targeted T cells: Addressingthe hostile tumor microenvironment”, Critical Frontiers Between Immunity andGene Therapy, International symposium, Pamplona, Spain11/16/2009 “Treatment of B cell malignancies with CD-19 targeted T cells” ImmunologyResearch Conference, CUNY Hunter College, New York, NY11/18/2009 “Initial results from a phase I clinical trial treating chemotherapy refractorychronic lymphocytic leukemia patients with autologous CD19-targeted T cells”,Cold Spring Harbor Laboratories Symposia: In Vivo Barriers to Gene Delivery,Cold Spring Harbor, NY6/15/2010 “Serious Adverse Events in Trials Utilizing Chimeric Antigen Receptors: Lessonsfor Trial Design.” National Institutes of Health, Office of BiotechnologyActivities Symposia: Gene Modified T cells: Challenges in Clinical Trial Design,Rockville MA8/3/2010 “Adoptive T cell therapy of B cell malignancies: Of mice and men”, Departmentof Microbiology and Immunology Seminar, Dartmouth Medical School, Lebanon,NH09/26/2010 “CAR modified T cells, lymphodepletion, and the hostile tumormicroenvironment: Where do we go from here?”, ATTACK, 3rd Cellular Therapyof Cancer Symposium, Montpellier, France3/3/2011 “A multi-center clinical consortium to investigate the biology and clinical efficacyof autologous T cells genetically targeted to the CD19 antigen in patients with Bcell malignancies”, Clinical Trials and Translational Research AdvisoryCommittee 13 th Meeting, National Cancer Institute, Bethesda, MD3/8/2011 “Adoptive cell therapy of caner: Building a better T cell”, Hematology/OncologyGrand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY3/10/2011 “Adoptive T cell Therapies targeting CD19+ malignancies , from mouse modelsto clinical translation”, Translational Research Seminar Series, Memorial Sloan-Kettering Cancer Center, New York, NY4/10/2011 “Genetically targeted T cells further modified to secrete IL-12 exhibit enhanced invivo eradication of targeted cells in the absence of prior lymphodepletion” ColdSpring Harbor Laboratory Stem Cell Engineering and Cell-Based TherapiesMeeting, Cold Spring Harbor, NY11